Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
10 Cards in this Set
- Front
- Back
Enbrel (etanercept) Clearance |
Receptor-mediated processes
-->increased plasma levels upon repeated dosing Hepatobiliary and renal -->predicted metabolic processes |
|
Rituxan (rituximab) Clearance |
Receptor mediated processes including Ab-mediated cytotoxic (ADCC) pathways Hepatobiliary and renal elimination of catabolized Ab molecules (predicted) |
|
Lantis (insulin glargine) Clearance |
Renal and hepatic
|
|
Avonex (interferon beta-1a) Clearance |
Renal elimination (predicted) |
|
Omalizumab (Xolair) Receptor |
binds to circulating IgE in plasma to form an inactive complex as part of its MOA |
|
Bevacizumab (Avastin) Receptor |
binds to circulating VEGF in the plasma to form an inactive complex as part of its MOA |
|
Muromanab (OKT3) Immunogenicity |
For allograft rejection 25% |
|
Abciximab (Reopro) Immunogenicity |
for angioplasty 6-44% |
|
Rituximab (Rituxan) Immunogenicity |
For Non-Hodgkin lymphoma 11% |
|
Infliximab (Remicade) Neutralizing Ab |
Chimeric IgG1k MAb ¼ pts develop HACA -->decrease t ½ from 190 to 48hrs |